Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 51-60

  Hornick, Jason L ^a   Khawli, Leslie A ^a   Hu, Peisheng ^a   Sharifi, Jahangir ^a   Khanna, Chand ^b   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CHIMERIC ANTIBODY; HYBRID PROTEIN; IDOXURIDINE; INTERLEUKIN 2; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY CYT 351; MONOCLONAL ANTIBODY NR LU 10; MONOCLONAL ANTIBODY TNT 3; N(G) METHYLARGININE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNOTHERAPY; COLON TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE TUMOR; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; LUNG NEOPLASMS; MICE; MICE, NUDE; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0032926185     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Jain, R. K. Delivery of molecular medicine to solid tumors. Science (Washington DC), 27: 1079-1080, 1996.
2. Wilder, R. B., DeNardo, G. L., and DeNardo, S. J. Radioimmuno-therapy: recent results and future directions. J. Clin. Oncol., 14: 1383-1400, 1996.
3. Buchsbaum, D. J. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res., 55(Suppl. 23): 5729s-5732s, 1995.
4. Vriesendorp, H. M., Quadri, S. M., Andersson, B. S., and Dicke, K. A. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp. Hematol., 24: 1183-1190, 1996.
5. Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res., 50(Suppl. 3): 814s-819s, 1990.
6. Sands, H., and Jones, P. L. Physiology of monoclonal antibody accretion by tumors. Cancer Treat. Res., 57: 97-122, 1990.
7. Epstein, A. L. New approaches to improved antibody targeting. In: R. E. Henkin (ed.), Nuclear Medicine, pp. 516-533. St. Louis: Mosby-Year Book, 1996.
8. Khawli, L. A., Miller, G. K., and Epstein, A. L. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer (Phila.), 73: 824-831, 1994.
9. Smith, K. A. Lowest dose interleukin-2 immunotherapy. Blood, 81: 1414-1423, 1993.
10. Oppenheim, M. H., and Lotze, M. T. Interleukin-2: solid-tumor therapy. Oncology, 51: 154-169, 1994.
11. Rosenstein, M., Ettinghausen, S. E., and Rosenberg, S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. Immunology, 737: 1735-1742, 1986.
12. Ettinghausen, S. E., Puri, R. K., and Rosenberg, S. A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst., 80: 177-188, 1988.
13. Siegel, J. P., and Puri, R. K. Interleukin-2 toxicity. J. Clin. Oncol., 9: 694-704, 1991.
14. LeBerthon, B., Khawli, L. A., Alauddin, M., Miller, G. K., Charak, B. S., Mazumder, A., and Epstein, A. L. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immuno-conjugate. Cancer Res., 51: 2694-2698, 1991.
15. Epstein, A. L., Khawli, L. A., Hornick, J. L., and Taylor, C. R. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res., 55: 2673-2680, 1995.
16. Hornick, J. L., Sharifi, J., Khawli, L. A., Hu, P., Biela, B. H., Mizokami, M. M., Yun, A., Taylor, C. R., and Epstein, A. L. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother. Radiopharm., 13: 255-268, 1998.
17. Cullen, B. R. Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell, 46: 973-982, 1986.
18. Epstein, A. L., Chen, F-M., and Taylor, C. R. A novel method for the detection of necrotic lesions in human cancers. Cancer Res., 48: 5842-5848, 1988.
19. Hornick, J. L., Khawli, L. A., Hu, P., Lynch, M., Anderson, P. M., and Epstein, A. L. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood, 89: 4437-4447, 1997.
20. Colcher, D., Hand, P. H., Nuti, M., and Schlom, J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA, 78: 3199-3203, 1981.
21. Varki, N. M., Reisfeld, R. A., and Walker, L. E. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res., 44: 681-687, 1984.
22. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res., 7: 927-936, 1987.
23. Israeli, R. S., Powell, C. T., Fair, W. R., and Heston, W. D. W. Molecular cloning of a complementary DNA encoding a prostatespecific membrane antigen. Cancer Res., 53: 227-230, 1993.
24. Israeli, R. S., Powell, C. T., Corr, J. G., Fair, W. R., and Heston, W. D. W. Expression of the prostate-specific membrane antigen. Cancer Res., 54: 1807-1811, 1994.
25. Hu, P., Glasky, M. S., Yun, A., Alauddin, M. M., Hornick, J. L., Khawli, L. A., and Epstein, A. L. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum. Antib. Hybrid., 6: 57-67, 1995.
26. Pulvertaft, R. J. V. Cytology of Burkitt's tumour (African lymphoma). Lancet, 7: 238-240, 1964.
27. Ohsugi, Y., Gershwin, M. E., Owens, R. B., and Nelson-Rees, W. A. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X-irradiated nude mice. J. Natl. Cancer Inst., 65: 715-718, 1980.
28. Tom, B. H., Rutzky, L. P., Jakstys, M. M., Oyasu, R., Kaye, C. I., and Kahan, B. D. Human colonie adenocarcinoma cells. I. Establishment and description of a new line. In Vitro (Rockville), 12: 180-191, 1976.
29. Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., and Parks, W. P. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst., 57: 1417-1423, 1973.
30. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
31. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
32. Epstein, A. L., Marder, R. J., Winter, J. N., and Fox, R. I. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. J. Immunol., 133: 1028-1036, 1984.
33. Frankel, M. E., and Gerhard, W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay: an analysis of the interaction between hybridoma proteins and influenza virus. Mol. Immunol., 16: 101-106, 1979.
34. G-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs. J. Appl. Phys., 76: 1130-1137, 1994.
35. Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., and Yarranton, G. T. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Bio/Technology, 10: 169-175, 1992.
36. Hu, P., Hornick, J. L., Glasky, M. S., Yun, A., Milkie, M. N., Khawli, L. A., Anderson, P. M., and Epstein, A. L. A chimeric Lym1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res., 56: 4998-5004, 1996.
37. Gillies, S. D., Young, D., Lo, K-M., and Roberts, S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjugate Chem., 4: 230-235, 1993.
38. Harvill, E. T., Fleming, J. M., and Morrison, S. L. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J. Immunol., 157: 3165-3170, 1996.
39. Becker, J. C., Pancook, J. D., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med., 183: 2361-2366, 1996.
40. Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA, 93: 7826-7831, 1996.
41. Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. Long-lived and transferable tumor immunity in mice following targeted interleukin 2 therapy. J. Clin. Invest., 98: 2801-2804, 1996.
42. Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., and Rosenberg, S. A. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (Phila.), 58: 2764-2772, 1986.
43. Margolin, K. A., Rayner, A. A., Hawkins, M. J., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., Roper, M., Parkinson, D. R., Wiernik, P. H., Creekmore, S. P., and Boldt, D. H. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol., 7: 486-498, 1989.
44. Reisfeld, R. A., and Gillies, S. D. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy. J. Clin. Lab. Anal., 10: 160-166, 1996.
45. Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, C. A. Y., Custer, M. C., and Rosenberg, S. A. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol., 135: 2865-2875, 1985.
46. Goldenberg, D. M. Monoclonal antibodies in cancer detection and therapy. Am. J. Med., 94: 297-312, 1993.
47. 131I-CC49) when given in combination with γ-interferon. Cancer Res., 53: 600-608, 1993.
48. Murray, J. L., Macey, D. J., Grant, E. J., Rosenblum, M. G., Kasi, L. P., Zhang, H-Z., Katz, R. L., Rieger, P. T., LeBherz, D., Bhadkamkar, V., Greiner, J. W., Schlom, J., and Podoloff, D. A. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following α-interferon treatment. Cancer Res., 55(Suppl. 23): 5925s-5928s, 1995.
49. Russell, S. M., Krauer, K. G., McKenzie, I. F. C., and Pietersz, G. A. Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy. Cancer Res., 50: 6028-6033, 1990.
50. Folli, S., Pèlegrin, A., Chalandon, Y., Yao, X., Buchegger, F., Lienard, D., Lejeune, F., and Mach, J-P. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int. J. Cancer, 53: 829-836, 1993.
51. Rowlinson-Busza, G., Maraveyas, A., and Epenetos, A. A. Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model. Br. J. Cancer, 71: 660-665, 1995.
52. Thakur, M. L., DeFulvio, J., Tong, J., John, E., McDevitt, M. R., and Damjanov, I. Evaluation of biological response modifiers in the enhancement of tumor uptake of technetium-99m labeled macromolecules. J. Immunol. Methods, 752: 209-216, 1992.
53. DeNardo, G. L., DeNardo, S. J., Lambom, K. R., Van Hoosear, K. A., and Kroger, L. A. Enhancement of tumor uptake of monoclonal antibody in nude mice with PEG-IL-2. Antib. Immunoconjug. Radiopharm., 4: 859-870, 1991.
54. Kassis, A. I., and Adelstein, S. J. Preclinical animal studies with radioiododeoxyuridine. J. Nucl. Med., 57(Suppl.): 10S-12S, 1996.
55. 186Re-la-beled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice. Cancer Res., 50: 7973-7978, 1990.
56. Breitz, H. B., Sullivan, K., and Nelp, W. B. Imaging lung cancer with radiolabeled antibodies. Semin. Nucl. Med., 23: 127-132, 1993.
57. 186Re-labeled monoclonal antibody: methods and results. Cancer Res., 55(Suppl. 23): 5817s-5822s, 1995.
58. Lopes, A. D., Davis, W. L., Rosenstraus, M. J., Uveges, A. J., and Gilman, S. C. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res., 50: 6423-6429, 1990.
59. Chengazi, V. U., Feneley, M. R., Ellison, D., Stalteri, M., Granowski, A., Granowska, M., Nimmon, C. C., Mather, S. J., Kirby, R. S., and Britton, K. E. Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351). J. Nucl. Med., 38: 675-682, 1997.
60. Kahn, D., Williams, R. D., Haseman, M. K., Reed, N. L., Miller, S. J., and Gerstbrein, J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J. Clin. Oncol., 16:284-289, 1998.
61. Samlowski, W. E., Yim, C-Y., McGregor, J. R., Kwon, O-D., Gonzales, S., and Hibbs, J. B. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice. J. Immunother., 18: 166-178, 1995.
62. G-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin-2-induced capillary leak syndrome in healthy mice. J. Immunother., 18: 210-220, 1996.
63. Fukumura, D., Yuan, F., Endo, M., and Jain, R. K. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am. J. Pathol., 150: 713-725, 1997.